Guideline-recommended CHF drugs were frequently prescribed (ACE-I 71%, beta-blockers 65%), but target doses were reached in only 49% for ACE-I and 18% for beta-blockers.
Cross-Sectional (n=1,919)
Yes
BACKGROUND: Recent registries have shown that recommended drugs for the treatment of chronic heart failure (CHF) are under-prescribed in daily practice. AIMS: To determine prescription rates of CHF drugs, and to assess predictive factors for drug prescription using data from a large panel of French cardiologists. METHODS AND RESULTS: We included 1919 outpatients, with NYHA class II-IV heart failure and a left ventricular ejection fraction 75 years was an independent factor associated with under-prescription of ACE-I-ARBs, beta-blockers or spironolactone. Renal failure was associated with a lower prescription of ACE-I-ARB and spironolactone, and asthma was a predictor of under-prescription of beta-blockers. CONCLUSIONS: In this contemporary survey, prescription rates of CHF drugs were higher than previously reported. However, dosages were lower than those recommended in guidelines. Age remained an independent predictor of under-prescription of CHF drugs.
Groote et al. (Mon,) conducted a cross-sectional in Chronic heart failure (n=1,919). Guideline-recommended chronic heart failure drugs was evaluated on Prescription rates of CHF drugs and achievement of target doses. Guideline-recommended CHF drugs were frequently prescribed (ACE-I 71%, beta-blockers 65%), but target doses were reached in only 49% for ACE-I and 18% for beta-blockers.